The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression ... The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato ...

Johnson & Johnson's Spravato therapy for treatment-resistant ... "This provides further evidence for the use of esketamine nasal spray in this difficult-to-treat population and offers hope for ...

The United States Food and Drug Administration (FDA) has approved Spravato (esketamine), a nasal spray from Johnson & Johnson, as a stand-alone therapy for adults with major depressive disorder ...

Called Spravato, a brand name for esketamine, and developed by Johnson & Johnson, the drug is a nasal spray designed to treat ... And upon careful review, they felt Johnson & Johnson's new drug ...

The remaining 20% is their coinsurance. S-ketamine, or esketamine (Spravato), is an FDA-approved nasal spray that doctors and healthcare professionals may prescribe for major depressive disorder ...

The analyst equates COMP360 to Spravato 2.0. Johnson & Johnson’s JNJ Spravato (esketamine) is a nasal spray for TRD and major depressive disorder (MDD), selling over ~$1 billion annually.

That's why we offer a range of services, including medication management, therapy, Suboxone/Buprenorphine/Subutex, and innovative treatments such as Esketamine (Spravato ; nasal spray).